Literature DB >> 30904142

Total abdominal colectomy is cost-effective in treating colorectal cancer in patients with genetically diagnosed Lynch Syndrome.

Boxiang Jiang1, Asya Ofshteyn1, Jay J Idrees1, Matthew Giglia2, Carlos Gallego3, Sharon L Stein1, Emily Steinhagen4.   

Abstract

BACKGROUND: Lynch syndrome (LS) has a 80% lifetime risk of developing colorectal cancer and metachronous cancer. No studies have examined the quality adjusted life expectancy after SEG or TAC for LS patients, which this study was aiming for. If TAC offers a higher quality adjusted life year (QALY) to SEG in LS patients, preoperative diagnosis of LS is critical as it alters the recommended surgical procedure.
METHODS: A Markov decision tree was constructed using Treeage software to compare QALY of LS patients following SEG or TAC. Probabilities, cost, and utility were obtained from literature. Cost-effectiveness analyses were performed.
RESULTS: TAC dominates SEG as both the life-saving and cost-saving strategy. TAC dominated SEG on QALY (17.80 vs 17.13 QALY) for a cohort of LS patients diagnosed at an average of 30 year old and followed every 2 years after initial surgery.
CONCLUSIONS: We conclude that TAC as the primary surgical option for LS patients diagnosed with Stage I-III colon cancer is cost-effective. Further cost-effectiveness study is recommended to include extra-colonic malignancies in LS patients.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Colectomy; Colorectal cancer; Cost-effectiveness analysis; Lynch syndrome

Year:  2019        PMID: 30904142     DOI: 10.1016/j.amjsurg.2019.03.011

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  1 in total

1.  Quadruple gastrointestinal cancer with discordance of mismatch repair protein deficiency and microsatellite instability suggesting Lynch syndrome.

Authors:  Satoshi Toyota; Ryota Nakanishi; Yu Miyashita; Shinichiro Yoshino; Yoshiaki Fujimoto; Tomoko Jogo; Qingjiang Hu; Kentaro Hokonohara; Yuichi Hisamatsu; Koji Ando; Yasue Kimura; Eiji Oki; Yoshinao Oda; Masaki Mori
Journal:  Int Cancer Conf J       Date:  2020-11-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.